Bausch & Lomb Inc.’s bid for a judgment upholding the validity of two patents related to PreserVision eye-health supplements ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of ... intraocular lenses, and eye surgery products, and made revenues of $4.15 billion last year.

BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...

Bausch Health Companies owns 88.4% of Bausch and Lomb. Saunders believes interested buyers undervalued the company's product pipeline, which includes new technologies for contact lenses, dry eye ...

Eyecare company Bausch + Lomb (NYSE:BLCO) reported in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the other hand, the company’s full-year revenue guidance of $4.98 billion at the ...

2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and ...